Plain-English translation of NCT07085234 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy drug called Iparomlimab/Tuvorlimab (QL1706) combined with chemotherapy to treat locally advanced nasopharyngeal cancer—a type of cancer in the upper back of the throat. You would receive three cycles of this combination treatment before moving on to standard radiation therapy with additional chemotherapy. The goal is to see if adding this new immunotherapy drug helps improve outcomes for people with this type of cancer.
Nasopharyngeal cancer is often diagnosed at an advanced stage, making it harder to treat. Researchers want to find out if this medication can help strengthen the body's immune system to fight cancer more effectively when combined with chemotherapy, potentially improving survival and quality of life.
You likely qualify if…
You likely don't qualify if…
You would receive induction therapy over several weeks, getting the new immunotherapy medication and three chemotherapy drugs in cycles. After completing three cycles, you would move on to concurrent chemoradiotherapy with standard cisplatin chemotherapy combined with radiation therapy, following normal clinical care. Throughout the trial, you'll have regular blood tests and imaging scans to monitor how well the treatment is working and to check for side effects.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
China